Zepbound Alternatives (2026 Guide)
Six meaningful alternatives compared by efficacy, monthly cost, FDA indication, and switching scenario. Verified against current Lilly, Novo Nordisk, and pipeline data.
Zepbound (tirzepatide) is the most effective FDA-approved GLP-1 for weight loss in 2026. The closest direct alternatives are Wegovy (semaglutide), which produces about 14.9% mean weight loss vs Zepbound's 21% at the highest dose, and Mounjaro, which is the same molecule prescribed under a different FDA indication (type 2 diabetes). Older options like Saxenda and newer pipeline drugs like orforglipron and retatrutide round out the landscape. Switching is medically reasonable for patients who can't tolerate tirzepatide, can't access it, or have insurance that covers a different option.
At-a-glance comparison
Four FDA-approved options and two pipeline drugs that are likely to launch within 12 to 24 months. Read the detailed cards below for switching guidance.
| Drug | Generic | Form | Mean weight loss | Self-pay |
|---|---|---|---|---|
| Wegovy | semaglutide | Weekly injection (pen) or daily oral pill | About 14.9% (2.4 mg pen, 68 weeks); 20.7% (Wegovy HD 7.2 mg, 72 weeks); 13.6% (25 mg pill, 64 weeks) | $199-$349 / month pen via NovoCare; $149-$299 / month pill via NovoCare |
| Mounjaro | tirzepatide | Weekly injection | 11 kg (~24 lb) average at 15 mg in T2D patients over 40 weeks (SURPASS-2) | Not eligible for Lilly Self Pay program (Self Pay is Zepbound-only). Savings Card brings cost to $25 with commercial insurance covering Mounjaro for T2D, $499 if not covered. |
| Saxenda | liraglutide | Daily injection | About 6 to 8% over 56 weeks (SCALE trials) | Limited self-pay programs; Savings Card brings to $25 with commercial insurance |
| Compounded tirzepatide | tirzepatide (compounded) | Weekly injection (vial + syringe) | No controlled trial data; clinic-reported outcomes vary | Typically $199-$399 per month through telehealth programs that price by dose |
| Retatrutide | retatrutide | Weekly injection | About 24% at 12 mg over 48 weeks (TRIUMPH-1 phase 2 data) | Not yet approved |
| Foundayo (orforglipron) | orforglipron | Once-daily oral pill | About 12.4% among completers (11.1% regardless of completion) at the 36 mg trial high dose over 72 weeks in ATTAIN-1. Note: 36 mg was a trial-only dose; approved label tops out at 17.2 mg | LillyDirect $149-$349/month by dose; $25/month with Lilly Savings Card for eligible commercial insurance |
Each alternative in detail
Wegovy
semaglutide· Novo Nordisk- FDA-approved for chronic weight management with extensive trial data
- Available as both weekly injection and once-daily oral pill
- Wegovy HD 7.2 mg approaches Zepbound 15 mg weight-loss outcomes
- Novo Nordisk patient assistance program offers free Wegovy for income-eligible patients
- Mean weight loss at 2.4 mg is meaningfully lower than Zepbound 15 mg
- Single-mechanism (GLP-1 only) rather than dual GIP/GLP-1 like tirzepatide
- Pill formulation has lower efficacy than pen formulation
- List price is higher than Zepbound's
Choose Wegovy if your insurance covers it but not Zepbound, if you want an oral pill option (Wegovy is the only FDA-approved oral GLP-1 for weight loss), or if you prefer Novo Nordisk's pricing programs.
Mounjaro
tirzepatide· Eli Lilly- Identical active ingredient to Zepbound at the same doses
- Insurance coverage is broader for diabetes than for obesity
- Same manufacturer, same KwikPen formats, same titration
- Requires a type 2 diabetes diagnosis for the FDA-labeled indication
- Off-label use for weight loss is hard to get insurance to cover
- No cash-pay self-pay program (unlike Zepbound's $299-$449 via LillyDirect)
Choose Mounjaro only if you have type 2 diabetes. The drug is identical to Zepbound but the prescription has to match the FDA indication.
Saxenda
liraglutide· Novo Nordisk- Longer post-market safety record than tirzepatide or semaglutide
- FDA-approved in adolescents 12 and older for obesity
- Some insurance plans still cover Saxenda when newer GLP-1s are excluded
- Daily injection rather than weekly (much higher patient burden)
- Substantially less effective than Zepbound, Wegovy, or Mounjaro
- Manufacturer has not invested in updated formulations or pricing programs
Saxenda makes sense in narrow cases: pediatric weight management (the only FDA-approved GLP-1 for ages 12+), patients with insurance that explicitly covers it but not newer options, or patients who tolerated liraglutide previously and are reluctant to switch molecules.
Compounded tirzepatide
tirzepatide (compounded)· Various 503B and 503A compounding pharmacies- Substantially cheaper than branded Zepbound for cash-pay patients
- Dose-flexible, which makes it the only practical option for sub-label microdosing
- Available through telehealth programs that simplify ongoing access
- FDA shortage list status changed in February 2026, restricting new compounded prescriptions to specific medical-exception cases
- Quality varies between compounding pharmacies; not all are 503B-licensed
- No FDA approval, no peer-reviewed efficacy data on the compounded versions
Compounded tirzepatide became substantially harder to legally access after the February 2026 FDA shortage-list change. It remains available in specific medical-exception cases through licensed compounding pharmacies. For most patients, branded Zepbound through LillyDirect Self Pay ($299-$449) is now the cheaper and clearer path.
Retatrutide
retatrutide· Eli Lilly (investigational)- Triple-receptor agonist (GLP-1 + GIP + glucagon), the most ambitious mechanism in the class
- Higher mean weight loss in phase 2 than Zepbound's phase 3 data at comparable durations
- Lilly is targeting approval in late 2026 or 2027
- Not yet FDA-approved; not commercially available
- Phase 3 results not yet published as of April 2026
- Pricing strategy unknown (likely premium-positioned)
Not a current option; tracked here so patients on Zepbound understand the pipeline. Most patients should stay on their current regimen until retatrutide has FDA approval and post-launch real-world data.
Foundayo (orforglipron)
orforglipron· Eli Lilly- First oral GLP-1 without the Rybelsus empty-stomach restriction
- Non-peptide molecule means easier manufacturing and lower shortage risk
- FDA-approved April 1, 2026 and shipping now via LillyDirect
- Mean weight loss is lower than Zepbound at the highest dose (12.4% completers vs ~21%)
- Newer to market, less long-term real-world safety data than injectable GLP-1s
- Insurance coverage and prior authorization rules still settling at most plans
Switch from Zepbound to Foundayo only if injection refusal is non-negotiable, or if LillyDirect self-pay on Foundayo beats what you're paying for Zepbound. Otherwise Zepbound at 15 mg still produces more weight loss.
Factors that drive a switch
Most patients who change GLP-1s do so for one of these reasons. Talk to your prescriber before switching.
If your plan covers Wegovy but not Zepbound, switching to Wegovy is the most common clinical workaround. The molecule is different but the indication is the same.
LillyDirect Self Pay for Zepbound ($299-$449) is competitive with most cash-pay alternatives. Wegovy NovoCare Self-Pay is comparable. Compounded telehealth pricing is no longer the bargain it was before the February 2026 FDA shortage-list change.
If tirzepatide-class side effects (nausea, GI distress) are unmanageable at the lowest Zepbound dose, switching to single-mechanism semaglutide (Wegovy) sometimes produces a more tolerable profile. Some patients prefer the opposite for the same reason.
If you have type 2 diabetes, Mounjaro is the same drug at the same doses with broader insurance coverage and a different Savings Card structure.
Saxenda is the only FDA-approved GLP-1 for adolescents 12 and older. Zepbound, Wegovy, and Mounjaro are adults-only at this writing.
Foundayo (orforglipron) was FDA-approved April 1, 2026 and is the first oral GLP-1 specifically for weight management without Rybelsus's empty-stomach restriction. Wegovy pill (oral semaglutide for weight loss) and Rybelsus (oral semaglutide for diabetes) remain alternatives where Foundayo is unavailable or unaffordable.
Frequently asked questions
Not sure which alternative actually fits your situation?
Take our 90-second quiz to get matched with a clinic prescribing your best option, whether that's Zepbound itself or one of the alternatives covered above.
Drug efficacy and dosing data are taken from FDA-approved prescribing information for Zepbound, Wegovy, Mounjaro, and Saxenda, and from published phase 2 and phase 3 trial results for retatrutide (TRIUMPH program) and orforglipron (ATTAIN-1, ACHIEVE program). Pricing reflects manufacturer list prices and self-pay program pricing as of the last_verified date.